Skip to main content
Equibles

Anthony Mancini

COO

Genmab A/S (GMAB)
Revolution Medicines, Inc. (RVMD)

Equibles does not estimate personal net worth.

Get an email with a short summary when Genmab A/S publishes a filing, an earnings call transcript or a press release.

Get GMAB alerts

About Anthony Mancini

Anthony Mancini is recorded as COO at Genmab A/S (GMAB). Anthony Mancini has spoken on 13 earnings calls across 2 companies, most recently for Revolution Medicines, Inc. on August 5, 2026. Those appearances were for Genmab A/S (GMAB) and Revolution Medicines, Inc. (RVMD). Genmab A/S is classified in the Biotechnology industry within the Healthcare sector. Revolution Medicines, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Revolution Medicines, Inc. includes Mark Goldsmith (CEO and Board Member), Jack Anders (CFO), Margaret Horn (COO) and 7 others.

Anthony Mancini on recent calls

“We've been preparing for some time and are ready for a successful CDAC launch in the U.S. And as we think about commercialization infrastructure, there are parts of that commercialization infrastructure that are broad and that can apply to our future indications.”
Other, Revolution Medicines, Inc. Q2 FY2026 Earnings Call ·
“On the colorectal cancer data coming up, can you help guide expectations on how to think about combination with EGFR given overlapping rash and how to think about mitigation or how to interpret results given higher efficacy, but also trying to mitigate rash in that strategy.”
Other, Revolution Medicines, Inc. Q1 FY2026 Earnings Call ·
“In Q2 and in the first half of 2024, performance across our two key revenue streams, Royalty Medicines and Genmab commercialized medicines continued to demonstrate strong growth.”
COO, Genmab A/S Q2 FY2024 Earnings Call ·
“In Q1, product performance across our two key revenue streams, royalty medicines and Genmab commercialized medicines showed very strong growth. Our portfolio includes six royalty medicines: DARZALEX, KESIMPTA, TEPEZZA, TECVAYLI, RYBREVANT and TALVEY.”
COO, Genmab A/S Q1 FY2024 Earnings Call ·
“I'll review our Q4 and full-year 2023 product revenue performance on Slide 7. Our business is comprised of two key revenue streams, royalty medicines shown here and in-market or launch medicines, which we commercialize ourselves with partners.”
COO, Genmab A/S Q4 FY2023 Earnings Call ·

Affiliation history

Company network

Leadership on record at Revolution Medicines, Inc.

Recent activity

Show 1 earlier activities